Trodelvy
Showing 1 - 25 of 29
Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Sacituzumab govitecan
- (no location specified)
Nov 9, 2023
Gastrointestinal Cancer Trial (Capecitabine, Sacituzumab govetican)
Not yet recruiting
- Gastrointestinal Cancer
- Capecitabine
- Sacituzumab govetican
- (no location specified)
Oct 2, 2023
Triple Negative Breast Cancer Trial (Sacituzumab govitecan, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Sacituzumab govitecan
- Pembrolizumab
- (no location specified)
Oct 5, 2023
Localized Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma Trial in Cleveland (Sacituzumab
Not yet recruiting
- Localized Muscle Invasive Bladder Urothelial Carcinoma
- Muscle-Invasive Bladder Carcinoma
- Sacituzumab govitecan
- Adaptive Radiotherapy
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Apr 18, 2023
Triple Negative Breast Cancer, Metastatic Breast Cancer Trial (Sacituzumab govitecan)
Not yet recruiting
- Triple Negative Breast Cancer
- Metastatic Breast Cancer
- Sacituzumab govitecan
- (no location specified)
Jan 23, 2023
Metastatic Urothelial Carcinoma Trial in Tampa, Boston (Ipilimumab, Nivolumab, Sacituzumab govitecan)
Recruiting
- Metastatic Urothelial Carcinoma
- Ipilimumab
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 24, 2023
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,
Not yet recruiting
- Her 2 Positive Breast Cancer
- +2 more
- Sacituzumab Govitecan
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 25, 2023
Early-stage Breast Cancer Trial in Heidelberg (Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib)
Not yet recruiting
- Early-stage Breast Cancer
- Atezolizumab 1200 mg in 20 ML Injection
- +5 more
-
Heidelberg, Baden-Wuerttemberg, GermanyNational Center for Tumor Diseases
Sep 13, 2022
Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in
Recruiting
- Urothelial Cancer
- +3 more
- Sacituzumab Govitecan (SG)
- Enfortumab vedotin-ejfv (EV)
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 28, 2022
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle
Recruiting
- Muscle Invasive Bladder Carcinoma
- +2 more
- Lymphadenectomy
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 9, 2023
Urothelial Bladder Carcinoma Trial in Spain (Sacituzumab govitecan, Zimberelimab, Domvanalimab)
Not yet recruiting
- Urothelial Bladder Carcinoma
- Sacituzumab govitecan
- +2 more
-
Santiago De Compostela, A Coruña, Spain
- +9 more
Nov 14, 2023
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab
Recruiting
- Locally Advanced or Unresectable Metastatic Breast Cancer
- Stage IV Breast Cancer
- Sacituzumab Govitecan-hziy
- +3 more
-
Marietta, Georgia
- +1 more
Apr 21, 2023
Metastatic Breast Cancer, Chemo-induced Alopecia Trial in Boston (Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan)
Recruiting
- Metastatic Breast Cancer
- Chemotherapy-induced Alopecia
- Paxman Scalp Cooling System
- +3 more
-
Boston, Massachusetts
- +1 more
Jan 18, 2022
NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sacituzumab Govitecan
- Pembrolizumab
-
Marietta, Georgia
- +2 more
Jan 27, 2023
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer Trial in United States (Pembrolizumab, Sacituzumab
Recruiting
- Invasive Breast Cancer
- +3 more
- Pembrolizumab
- Sacituzumab Govitecan
-
Atlanta, Georgia
- +7 more
Nov 14, 2022
Triple Negative Breast Cancer Trial in United States (Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine)
Recruiting
- Triple Negative Breast Cancer
- Sacituzumab govitecan-hziy (SG)
- +2 more
-
Glendale, Arizona
- +7 more
Jan 26, 2023
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer Trial in United States (Atezolizumab, Sacituzumab govitecan)
Recruiting
- Breast Cancer
- +3 more
- Atezolizumab
- Sacituzumab govitecan
-
San Francisco, California
- +8 more
May 25, 2022
Metastatic Solid Tumor Trial in Belgium, France, United States (Sacituzumab Govitecan-hiy)
Enrolling by invitation
- Metastatic Solid Tumor
- Sacituzumab Govitecan-hiy
-
San Francisco, California
- +17 more
Jan 6, 2023
Advanced Solid Tumors or Triple-negative Breast Cancer Trial in Japan (Sacituzumab Govitecan-hziy)
Recruiting
- Advanced Solid Tumors or Triple-negative Breast Cancer
- Sacituzumab Govitecan-hziy
-
Aichi, Japan
- +21 more
Dec 1, 2022
Triple Negative Breast Cancer Trial in United States (Trilaciclib, Sacituzumab Govitecan-hziy)
Recruiting
- Triple Negative Breast Cancer
- Trilaciclib
- Sacituzumab Govitecan-hziy
-
Chandler, Arizona
- +21 more
Oct 25, 2022
Metastatic Urothelial Cancer Trial in France, United States (Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin)
Recruiting
- Metastatic Urothelial Cancer
- Sacituzumab Govitecan-hziy
- +7 more
-
Tucson, Arizona
- +44 more
Jan 9, 2023
Metastatic Breast Cancer Trial in China, Korea, Republic of, Taiwan (sacituzumab govitecan (IMMU-132), Eribulin Mesylate
Recruiting
- Metastatic Breast Cancer
- sacituzumab govitecan (IMMU-132)
- +4 more
-
Beijing, China
- +43 more
Apr 19, 2022
HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)
Recruiting
- HRD Cancer
- +2 more
- Berzosertib
- Sacituzumab Govitecan
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
HER2-negative Breast Cancer, Triple Negative Breast Cancer Trial in France, Germany, Ireland (Capecitabine, Carboplatin,
Recruiting
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- Capecitabine
- +3 more
-
Brasschaat, Belgium
- +161 more
Nov 2, 2022